07:22 AM EDT, 05/15/2025 (MT Newswires) -- Merck ( MRK ) said Thursday its late-stage trial evaluating its cancer drug Keytruda in combination with chemotherapy with or without bevacizumab met its primary endpoint of progression-free survival in patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers.

The trial also met a secondary endpoint of overall survival in patients whose tumors express PD-L1, the company said.

The trial showed no new safety signals for Keytruda as the safety profile remained consistent with that observed in previously reported studies.

Merck ( MRK ) said the study is continuing and that the final overall survival results for the entire study population will be evaluated at a future analysis.

The company's shares were up about 1% in recent premarket activity on Thursday.